| Clinical data | |
|---|---|
| Other names | MYCO006 |
| Drug class | Entactogen;Empathogen |
MYCO-006 is anMDMA-likeentactogen that is under development for the treatment ofpsychiatric disorders.[1][2][3][4] It is a short-acting and fast-onset MDMAanalogue.[3][4] Based onanimal studies, it is predicted that MYCO-006 will have aduration of 1 to 2 hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4 times as fast as MDMA.[4] MYCO-006 is being developed byMydecine.[1][2][3][4] As of February 2024, it is inpreclinical research.[1][2] Thechemical structure of MYCO-006 does not yet appear to have been disclosed.[1][2]5-BZT-MDMA and6-BZT-MDMA were described in Mydecine's patent for short-acting MDMA analogues.[5][6][7]
Just last month Mydecine announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs had been specifically designed by experts at Mydecine to have a shorter half-life than traditional MDMA. The company has named this family of novel molecules MYCO-006 and applied for patent coverage with the World Intellectual Property Organization.
The effects from the company's MYCO-006 compounds last for only two hours and set in four times as fast [...] The biotech company announced the results of its preclinical mice studies on Monday examining its proprietary MDMA drug family MYCO-006. [...] MYCO-006 compounds have the same therapeutic effect as standard MDMA but have demonstrated a shorter half-life duration in animal research. The projected duration of the MYCO-006 compounds is around one to two hours, which is approximately one-third the length of the conventional six to eight hours for regular MDMA. Additionally, the onset of MYCO-006 compounds is expected to be four times faster than Gen-1 or regular MDMA. The drugs are intended to treat conditions such as PTSD, chronic pain, depression and addiction.
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byadding missing information. |